ALB and GLB are two important components of systemic inflammation, and the combination of these two markers (AGR) has been reported to be significant and validated in several types of cancers, including nasopharyngeal carcinoma, small-cell lung cancer and hepatocellular carcinoma [15–18]. This evidence concerns the gene ALB and small cell lung carcinoma.